

**Ohio Department of Job and Family Services (ODJFS)  
Drug Utilization Review (DUR) Board  
Quarterly Meeting  
November 17th, 2010**

The quarterly meeting of the ODJFS DUR Board was called to order at 12:00 PM in room South A of the 31<sup>st</sup> floor of the Riffe Building, 77 S. High St. Columbus, Ohio. Thomas Gretter, MD, presided. The following Board members were present:

David Brookover, RPh  
Michael Farrell, MD  
Robert Kubasak, RPh  
Kevin Mitchell, RPh,  
Donald Sullivan, RPh, PhD

Also present were Margaret Scott, RPh, DUR Administrator, Jill Griffith, RPh, DUR Director, and from the University of Cincinnati College of Pharmacy, Pam Heaton RPh, PhD and Bob Cluxton, RPh, PhD. J. Layne Moore, MD were absent. Approximately 20 observers were present, most representing pharmaceutical manufacturers.

Reading, Correction & Approval of Previous Minutes:

The September 15th, 2010, DUR Board minutes were approved. (1<sup>st</sup> R. Kubasak, 2<sup>nd</sup> D. Sullivan).

DUR Committee Report:

J. Griffith gave the DUR committee report.

In September and October, the DUR Committee re-reviewed 431 profiles of patients felt to be overusing rescue inhalers. The prescriber letters mailed last year suggested the addition of controller therapy if patients were indeed overusing rescue inhalers. Profiles were deemed improved if a new controller therapy were added and/or if the patient used less albuterol. Upon re-review 261 of the 431 profiles reviewed were improved (60.5%); 140 of the 431 not improved (32.5%) and 30 of the 431 lost to follow-up (7%).

In November, the DUR Committee looked at 213 profiles of patients on two or more long-acting stimulant products concurrently. Drugs reviewed included Adderall XR, Concerta, Daytrana, Dexedrine Spansule, Focalin XR, Metadate CD, Ritalin LA, Vyvanse, and their generics. The committee also looked at 1,955 patients on different strengths of the same long acting product. For example, patients on Concerta 36 mg and 18 mg daily were reviewed. The product comes as a 54 mg tablet. Prescribers would be asked to evaluate the safety and need for multiple doses of long-acting stimulants that are designed to be taken once daily and are schedule II controlled substances. We also ask the prescriber to consider the possibility of diversion and provide them with the patient profile. A draft prescriber letter, response form, thank you letter and Ohio Automated Rx Reporting System (OARRS) registration instructions were submitted to

the Board for review. Suggested edits to the letter included adding the OARRS website address to the body of the letter and including a table of drug cost. The Board expressed interest in hearing the written physician responses to the mailing. M. Scott said that there are edits in the claim system to prevent multiple doses of the same strength from being dispensed, but the edit does not go across doses. She suggested an edit in the system to allow only one daily dose long-acting stimulant product to be dispensed without prior authorization. The Board approved the new edit unanimously.

Health Plan Policy:

M. Scott discussed two pharmacy quality forum meetings. The first meeting included an overview of the Medicaid drug program presented by M. Scott. The second meeting included a presentation by Dr. Curtis Black about Medication Therapy Management (MTM).

M. Scott updated the Board about the Medicaid Information Technical System (MITS). The DUR program is getting a custom built RetroDUR program that has been delayed with no new operational date set.

Unfinished Business:

J. Griffith asked the Board for future DUR topic suggestions. D. Sullivan suggested an evaluation of appropriate use of HIV medications. P. Heaton asked if there are clear guidelines that can be used. R. Kubasak suggested focusing on patient compliance with HIV medications. HIV guidelines are available. D. Sullivan suggested that there are several tools available to improve compliance.

New Business:

M. Scott announced that Board member terms are two years long. Dr. Gretter, Dr. Sullivan, K. Mitchell and Dr. Moore are up for reappointment. Please consider continued membership with the DUR Board.

Elections were held. K. Mitchell was elected Chair (Gretter 1<sup>st</sup>, Sullivan 2<sup>nd</sup>) and M. Farrell elected CoChair (Gretter 1<sup>st</sup>, Kubasak 2<sup>nd</sup>).

Announcements:

The next meeting is scheduled for noon on Tuesday, February 8th. The meeting will be held on the 31<sup>st</sup> floor of the Riffe Building. The second quarter meeting will be held on Tuesday, May 10<sup>th</sup>. We will schedule the remainder of the year at the February meeting.

Adjournment:

T. Gretter adjourned the meeting at 12:33 PM.

Respectfully submitted:

---

Jill R.K. Griffith B.S., Pharm.D., DUR Program Director